A Phase II/III Randomized Trial Of Veliparib Or Placebo In Combination With Adjuvant Temozolomide In Newly Diagnosed Glioblastoma With Mgmt Promoter
Posted Date: May 15, 2019
- Investigator: Rekha Chaudhary
- Type of Study: Drug
The purpose of this study is to compare the effects, good or bad of the usual treatment (temozolomide) with or without the addition of the investigational drug veliparib for people whose brain tumors show a change in a small region of DNA (gene) called O6-methylguanine methyltransferase (MGMT). Your
Criteria:
To Be Eligible To Participate, Patients Must Have A Type Of Brain Tumor Called A Glioblastoma Multif
Keywords:
Cancer, Glioblastoma, Mgmt Promoter Hyperm, A071102, Brain Tumor
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com